Shopping Cart
Remove All
Your shopping cart is currently empty
Varisacumab (Synonyms: R 84 (antibody), GNR-011)
Catalog No. T80877 Copy Product Info
🥰Excellent
Varisacumab (R 84) is a sophisticated human recombinant monoclonal antibody target Vascular Endothelial Growth Factor A (VEGFA), thereby effectively neutralizing its interaction with both VEGFR1 and VEGFR2 receptors. Varisacumab (R 84) has demonstrated anti-angiogenic properties in preclinical models and is extensively utilized for research involving malignancy and microvascular complications of diabetes.
Varisacumab
Copy Product Info🥰Excellent
Catalog No. T80877
Synonyms R 84 (antibody), GNR-011
Varisacumab (R 84) is a sophisticated human recombinant monoclonal antibody target Vascular Endothelial Growth Factor A (VEGFA), thereby effectively neutralizing its interaction with both VEGFR1 and VEGFR2 receptors. Varisacumab (R 84) has demonstrated anti-angiogenic properties in preclinical models and is extensively utilized for research involving malignancy and microvascular complications of diabetes.
Varisacumab
Cas No. 1610010-60-0
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | Inquiry | Inquiry | Inquiry | |
| 5 mg | Inquiry | Inquiry | Inquiry |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Quotation
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Varisacumab (R 84) is a sophisticated human recombinant monoclonal antibody target Vascular Endothelial Growth Factor A (VEGFA), thereby effectively neutralizing its interaction with both VEGFR1 and VEGFR2 receptors. Varisacumab (R 84) has demonstrated anti-angiogenic properties in preclinical models and is extensively utilized for research involving malignancy and microvascular complications of diabetes. |
| Targets&IC50 | VEGFA:< 7 nM (Kd) |
| In vitro | In binding assays with human VEGF165, Varisacumab (r84) exhibited high affinity with an EC50 of 0.288 nM and inhibited VEGF-induced tube formation in HUVEC models [1]. |
| In vivo | In human breast cancer xenograft models, systemic administration of Varisacumab (r84) significantly reduced tumor volume and microvascular density [1]. |
| Synonyms | R 84 (antibody), GNR-011 |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Uniprot ID | |
| Target | VEGF-A |
| Cas No. | 1610010-60-0 |
| Isotype | IgG1 |
| Storage | Store at -20°C Shipping with blue ice/Shipping at ambient temperature. |
Citations
Calculator
Preview
Related Tags: buy Varisacumab | purchase Varisacumab | Varisacumab cost | order Varisacumab | Varisacumab in vivo | Varisacumab in vitro
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.